Takeda, CanBas, LG Life, 3M deal

CanBas granted Takeda exclusive, worldwide rights to develop and market CBP501 and undisclosed backup compounds to treat cancer. CBP501, a cell cycle G2 checkpoint

Read the full 246 word article

How to gain access

Continue reading with a
two-week free trial.